Stock comparison
Cencora
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
COR
Cencora
Market cap
$53.49B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | COR | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 65C | GMAB |
| Benjamin Graham | 73B | 64C | COR |
| Philip Fisher |
Side-by-side metrics
| Metric | COR | GMAB |
|---|---|---|
| Market cap | $53.49B | $16.5B |
| P/E (TTM) | 20.1x | 6.2x |
| EV/EBIT | 16.9x | 12.0x |
| ROIC (TTM) | 11.89% | 43.78% |
| Gross margin | 3.47% | 93.88% |
| Net margin | 0.78% | 18.23% |
| Revenue CAGR 5y | 10.7% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
COR leads on
- Revenue CAGR 5y10.7%vs -18.45%+158%
- EPS CAGR 5y1.76%vs -23.48%+107%
- Dividend yield0.89%vs 0.0%+100%
- Market cap$53.49Bvs $16.5B
More like GMAB
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.